Thanks, very interesting. My guess is the antibodies they're developing are against the CD4 binding arm on the HIV virus itself. The antibodies alone might not be 100% effective on their own but a powerful CCR5 blocker like leronlimab could boost effectiveness. Of course where CCR5 occupancy is 100% another antibody would be superfluous. They may also be developing antibodies against dual CXCR4/CCR5 dual strains where their antibody blocks CXCR4 binding and leronlimab could block CCR5.